Retina Clinical Trials: What Re-Acquisition In Retinal Imaging Is Really Costing Your Program

Retinal clinical trials often operate under the illusion that a failed OCT scan is merely a technical hiccup easily solved by a rescan. In reality, the true cost of poor imaging includes missed visit windows, cumbersome deviation filings, and escalated query backlogs. When nearly 45% of all screen failures are driven by imaging findings, the "hidden invoice" of a trial includes the most expensive line item of all: the lost patient.

Success in these trials isn't just about the hardware; it’s about the infrastructure established long before the patient enters the room. Most re-acquisition events are the fallout of systemic gaps—training inconsistencies, misaligned acquisition settings, and the absence of real-time quality control. By shifting the paradigm toward bringing high-fidelity imaging directly to the patient, sponsors can alleviate the scheduling pressures that typically degrade scan quality. This logistical shift does more than just clean up the data; it humanizes the process, historically slashing dropout rates from 30% to single digits. Prioritizing precision at the point of capture ensures that the path to a primary endpoint isn't derailed by preventable technical friction.